These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 20174727

  • 1. Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes.
    Saad AA, Awed NM, Abdel-Hafeez ZM, Kamal GM, Elsallaly HM, Alloub AI.
    Saudi Med J; 2010 Feb; 31(2):135-41. PubMed ID: 20174727
    [Abstract] [Full Text] [Related]

  • 2. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.
    J Clin Oncol; 2008 Oct 01; 26(28):4587-94. PubMed ID: 18662967
    [Abstract] [Full Text] [Related]

  • 3. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, Rosenwald A, Jack A, Sundstrom C, Cogliatti S, Trougouboff P, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Gisselbrecht C.
    J Clin Oncol; 2011 Nov 01; 29(31):4079-87. PubMed ID: 21947824
    [Abstract] [Full Text] [Related]

  • 4. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation.
    Costa LJ, Feldman AL, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Ansell SM.
    Br J Haematol; 2008 Jul 01; 142(3):404-12. PubMed ID: 18492096
    [Abstract] [Full Text] [Related]

  • 5. [Clinical characteristics, cell origin and prognosis of primary gastrointestinal diffuse large B-cell lymphoma: a report of 40 cases].
    Yang YL, Wang J, Zhao LZ, Gao ZF, Jing HM, Ke XY.
    Ai Zheng; 2008 Jun 01; 27(6):636-41. PubMed ID: 18570740
    [Abstract] [Full Text] [Related]

  • 6. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, Kim JE, Kim CW.
    Histopathology; 2008 Aug 01; 53(2):205-17. PubMed ID: 18752503
    [Abstract] [Full Text] [Related]

  • 7. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK, Hee SW, Quek R, Yap SP, Loong S, Tan L, Tao M, Lim ST.
    Ann Hematol; 2009 May 01; 88(5):417-24. PubMed ID: 18777110
    [Abstract] [Full Text] [Related]

  • 8. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
    Liu YH, Xu FP, Zhuang HG, Lai KC, Xie D, Luo DL, Li L, Luo XL, Xu J, Zhang MH, Zhang F, Li HM.
    Hum Pathol; 2008 Jun 01; 39(6):875-84. PubMed ID: 18440593
    [Abstract] [Full Text] [Related]

  • 9. Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?
    Laszlo D, Pruneri G, Andreola G, Radice D, Calabrese L, Rafaniello PR, Nassi L, Sammassimo S, Alietti A, Agazzi A, Vanazzi A, Martinelli G.
    Int J Surg Pathol; 2011 Aug 01; 19(4):417-24. PubMed ID: 19793830
    [Abstract] [Full Text] [Related]

  • 10. Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients.
    Zinzani PL, Broccoli A, Stefoni V, Musuraca G, Abruzzese E, De Renzo A, Cantonetti M, Bacci F, Baccarani M, Pileri SA.
    Cancer; 2010 Dec 15; 116(24):5667-75. PubMed ID: 20737566
    [Abstract] [Full Text] [Related]

  • 11. Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes.
    Watanuki-Miyauchi R, Kojima Y, Tsurumi H, Hara T, Goto N, Kasahara S, Saio M, Moriwaki H, Takami T.
    Pathol Int; 2005 Jun 15; 55(6):324-30. PubMed ID: 15943789
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
    Muris JJ, Meijer CJ, Vos W, van Krieken JH, Jiwa NM, Ossenkoppele GJ, Oudejans JJ.
    J Pathol; 2006 Apr 15; 208(5):714-23. PubMed ID: 16400625
    [Abstract] [Full Text] [Related]

  • 13. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma].
    Wen JJ, Liu ZB, Xu J, Xu CG.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Dec 15; 33(12):1004-9. PubMed ID: 23363791
    [Abstract] [Full Text] [Related]

  • 14. Comparison of two different immunohistochemical algorithms identifying prognostic subgroups of DLBCL.
    Jabłońska J, Jesionek-Kupnicka D, Potemski P, Kowalik A, Sygut J, Kordek R.
    Pol J Pathol; 2010 Dec 15; 61(3):124-32. PubMed ID: 21225494
    [Abstract] [Full Text] [Related]

  • 15. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y.
    Eur J Haematol; 2008 Dec 15; 81(6):448-53. PubMed ID: 18691256
    [Abstract] [Full Text] [Related]

  • 16. Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma.
    Nyman H, Jantunen E, Juvonen E, Elonen E, Böhm J, Kosma VM, Enblad G, Karjalainen-Lindsberg ML, Leppä S.
    Bone Marrow Transplant; 2008 Jul 15; 42(2):93-8. PubMed ID: 18391989
    [Abstract] [Full Text] [Related]

  • 17. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S.
    Eur J Haematol; 2009 May 15; 82(5):364-72. PubMed ID: 19141121
    [Abstract] [Full Text] [Related]

  • 18. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS.
    J Clin Oncol; 2008 Jan 20; 26(3):447-54. PubMed ID: 18086797
    [Abstract] [Full Text] [Related]

  • 19. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.
    Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, Kwak JY, Park BH, Park HS, Chung MJ, Kang MJ, Lee DG, Kim HS, Shim H, Moon WS.
    Am J Surg Pathol; 2008 Oct 20; 32(10):1523-31. PubMed ID: 18724249
    [Abstract] [Full Text] [Related]

  • 20. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
    Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, Warzocha K, Michallet AS, Robak T, Coiffier B, Salles G.
    Arch Immunol Ther Exp (Warsz); 2010 Apr 20; 58(2):131-41. PubMed ID: 20191326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.